NASDAQ:SNY - Nasdaq - US80105N1054 - ADR - Currency: USD
Overall SNY gets a fundamental rating of 6 out of 10. We evaluated SNY against 198 industry peers in the Pharmaceuticals industry. SNY has an excellent profitability rating, but there are some minor concerns on its financial health. SNY is valued quite cheap, while showing a decent growth score. This is a good combination! SNY also has an excellent dividend rating. With these ratings, SNY could be worth investigating further for value and dividend investing!.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 9% | ||
ROE | 15.37% | ||
ROIC | 15.58% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 22.04% | ||
PM (TTM) | 12.97% | ||
GM | 70.04% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.17 | ||
Debt/FCF | 3.04 | ||
Altman-Z | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.46 | ||
Quick Ratio | 0.74 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 13.57 | ||
Fwd PE | 9.99 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 19.12 | ||
EV/EBITDA | 5.2 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 4.36% |
51.98
-0.53 (-1.01%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 4.36% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 13.57 | ||
Fwd PE | 9.99 | ||
P/S | 1.22 | ||
P/FCF | 19.12 | ||
P/OCF | 12.39 | ||
P/B | 1.45 | ||
P/tB | 9.84 | ||
EV/EBITDA | 5.2 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 9% | ||
ROE | 15.37% | ||
ROCE | 19.55% | ||
ROIC | 15.58% | ||
ROICexc | 16.79% | ||
ROICexgc | 53.71% | ||
OM | 22.04% | ||
PM (TTM) | 12.97% | ||
GM | 70.04% | ||
FCFM | 6.39% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.17 | ||
Debt/FCF | 3.04 | ||
Debt/EBITDA | 0.56 | ||
Cap/Depr | 89.1% | ||
Cap/Sales | 3.47% | ||
Interest Coverage | -34.57 | ||
Cash Conversion | 38.03% | ||
Profit Quality | 49.3% | ||
Current Ratio | 1.46 | ||
Quick Ratio | 0.74 | ||
Altman-Z | N/A |